{
    "clinical_study": {
        "@rank": "36861", 
        "arm_group": [
            {
                "arm_group_label": "Levetiracetam", 
                "arm_group_type": "Experimental", 
                "description": "Levetiracetam 1000 mg/day"
            }, 
            {
                "arm_group_label": "Carbamazepine", 
                "arm_group_type": "Active Comparator", 
                "description": "Carbamazepine 400 mg/day"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine\n      Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese\n      population with newly or recently diagnosed Epilepsy who are experiencing Partial-Onset\n      Seizures (POS)."
        }, 
        "brief_title": "Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Epilepsy", 
            "Partial Seizures"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Seizures"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is of Chinese origin and \u2265 16 years of age\n\n          -  Subject is newly or recently diagnosed with Epilepsy, having experienced unprovoked\n             Partial-Onset Seizures (POS)\n\n          -  Subject has experienced at least 2 unprovoked seizures in the year preceding\n             randomization, of which at least 1 unprovoked seizure occurred in the 3 months\n             preceding randomization\n\n          -  Subject has had an Electroencephalogram (EEG) and a brain Computed Tomography (CT)\n             scan or brain Magnetic Resonance Imaging (MRI) scan consistent with a diagnosis of\n             Epilepsy with POS\n\n        Exclusion Criteria:\n\n          -  Subject tests positive for human leukocyte antigen major histocompatibility complex,\n             class I,B (HLA-B)* 1502 allele\n\n          -  Subject has a history or presence of seizures of other types than Partial-Onset\n             Seizures (POS)\n\n          -  Subject has only experienced type IA nonmotor seizures\n\n          -  Subject has a history or presence of seizures occurring only in clustered patterns\n\n          -  Subject has a history of clinical or Electroencephalogram (EEG) findings suggestive\n             of Idiopathic Generalized Epilepsy prior to randomization\n\n          -  Subject has current or previous diagnosis of pseudoseizures, conversion disorders, or\n             other nonepileptic ictal events that could be confused with seizures\n\n          -  Subject has a history of Status Epilepticus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "436", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954121", 
            "org_study_id": "N01364"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levetiracetam", 
                "description": "Immediate release film-coated tablets at strengths of 250 mg and 500 mg.\nUp-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)\nStabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid\nDown-titration Period (Week 30 up to Week 33)", 
                "intervention_name": "Levetiracetam", 
                "intervention_type": "Drug", 
                "other_name": "Keppra"
            }, 
            {
                "arm_group_label": "Carbamazepine", 
                "description": "Immediate release tablets at a strength of 200 mg.\nUp-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)\nStabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid\nDown-titration Period (Week 30 up to Week 33)", 
                "intervention_name": "Carbamazepine", 
                "intervention_type": "Drug", 
                "other_name": "Tegretol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carbamazepine", 
                "Etiracetam", 
                "Piracetam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Levetiracetam", 
            "Keppra", 
            "Monotherapy", 
            "China", 
            "Epilepsy", 
            "Partial-onset Seizures"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "13"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun City", 
                        "country": "China"
                    }, 
                    "name": "16"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "5"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "10"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }, 
                    "name": "4"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "1"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "20"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou City", 
                        "country": "China"
                    }, 
                    "name": "26"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "24"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China"
                    }, 
                    "name": "22"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kunming", 
                        "country": "China"
                    }, 
                    "name": "29"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }, 
                    "name": "21"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing City", 
                        "country": "China"
                    }, 
                    "name": "23"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing City", 
                        "country": "China"
                    }, 
                    "name": "6"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing City", 
                        "country": "China"
                    }, 
                    "name": "8"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qingdao", 
                        "country": "China"
                    }, 
                    "name": "27"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "15"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "18"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "14"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shijiazhuang", 
                        "country": "China"
                    }, 
                    "name": "19"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China"
                    }, 
                    "name": "3"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taiyuan", 
                        "country": "China"
                    }, 
                    "name": "9"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }, 
                    "name": "25"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "12"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China"
                    }, 
                    "name": "7"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xian", 
                        "country": "China"
                    }, 
                    "name": "17"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized, Parallel-group, Active-controlled Study Comparing the Efficacy and Safety of Levetiracetam to Carbamazepine Used as Monotherapy in Subjects Newly or Recently Diagnosed as Epilepsy and Partial-onset Seizures", 
        "overall_contact": {
            "last_name": "UCB Clinical Trial Call Center", 
            "phone": "+1 877 822 9493"
        }, 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects remaining seizure free during the 6-months Evaluation Period", 
            "safety_issue": "No", 
            "time_frame": "6-months Evaluation Period (From Week 4 to Week 30)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954121"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects retained in the study for the duration of the period covering the Up Titration Period, Stabilization Period, and Evaluation Period", 
                "safety_issue": "No", 
                "time_frame": "From Week 1 to Week 30"
            }, 
            {
                "measure": "Time to first seizure or discontinuation due to an Adverse Event (AE) / Lack of Efficacy (LOE) during the Evaluation Period", 
                "safety_issue": "No", 
                "time_frame": "From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)"
            }, 
            {
                "measure": "Time to first seizure during the Evaluation Period", 
                "safety_issue": "No", 
                "time_frame": "From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)"
            }, 
            {
                "measure": "Time to first seizure during the period covering the Up Titration Period, Stabilization Period, and Evaluation Period from the first dose of study drug", 
                "safety_issue": "No", 
                "time_frame": "From Randomization (Week 1) up to Evaluation Visit (Week 30)"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB Pharma SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}